introduction
Cancer is a disease of the aging. The number of elderly patients diagnosed with cancer is dramatically increasing and over a third of all cancers are diagnosed in patients >65 years. However, a significant knowledge gap on cancer in older patients exists, making geriatric oncology a critical area of research, indispensable to improve the management of this specific population.
In Europe, the estimated yearly incidence of soft-tissue sarcoma (STS) is 5 cases per 100 000 people [1] . The highest incidence of sarcomas is observed in patients aged between 75 and 84 years with a rate of ∼16% [2] . In the United States, this represents more than 1700 newly diagnosed patients yearly [2] . Compared with their younger counterparts, elderly patients diagnosed with STS present several differences. Indeed, older patients present worse prognosis, with higher grade and larger tumors at presentation [3, 4] . Moreover, recent studies have reported that elderly patients with localized STS may receive less intensive care compared with younger patients [3] [4] [5] [6] [7] .
Older patient age has been associated with a lower use of adjuvant chemotherapy [3] , radiotherapy [5, 8] , and definitive surgery, with an increased risk of positive surgical margins [9] . Moreover, this specific population is often excluded or very poorly represented in clinical trials [10] .
Chemotherapy is still the mainstay of treatment for patients with advanced disease. However, data on the management and outcome of very elderly patients with advanced STS are almost non-existent. The aim of this study issue was to address this specific issue.
patients and methods patients
This was a multicenter retrospective study involving 10 member institutions of the French Sarcoma Group and the Memorial Sloan Kettering Cancer Center (New York, NY; authorization: WA0209-04). The inclusion criteria were as follows: patients aged ≥75 years at diagnosis of advanced disease, histologically proven STS, and locally advanced (unresectable) and/or metastatic disease diagnosed between 1990 and 2011. Clinical and pathologic data were collected by reviewing medical records that were entered in a comprehensive database. In all cases, the histological diagnosis was established according to the World Health Organization Classification of Tumours [11] by an expert pathologist. The histological grade was determined as previously described according to the FNLCC grading system [12] . We used the age-adjusted Charlson comorbidity index to evaluate the severity of comorbidities [13] .
treatments and evaluation
The choice of treatment was at the discretion of the treating physician. Best supportive care (BSC) was defined as symptom control, palliative care without active treatment ( palliative chemotherapy, or palliative radiotherapy for a locally advanced and unresectable tumor). The best response to chemotherapy was evaluated by magnetic resonance imaging or computed tomography according to RECIST 1.1 [14] . Progression-free survival (PFS) was defined as the time from the start of the chemotherapy until disease progression, death, or last patient contact. Overall survival (OS) was defined as the time from the date of diagnosis until death or last patient contact. National Cancer Institute Common Toxicity Criteria (version 3.0) were used to classify adverse events.
statistical analysis
The statistical analysis of baseline demographics and clinical outcomes is based on all data available up to the cut-off date of July 2012. 
patient and tumor characteristics
The study population included 361 patients with equal gender distribution. This represented 13% of all the patients managed for an advanced STS in the participating institutions during the study period. The median age was 79 years (range 75-98). Over three quarters of patients had at least one metastatic site ( Table 1) .
patterns of care
One hundred and twenty-three patients (34%) were managed with BSC only (Table 2 ). In comparison with patients who received an active treatment, patients who received BSC only were most likely to be ≥80 years old (55% versus 38%, P = 0.001), to have PS ≥ 2 (54% versus 21%, P < 0.0001), Charlson comorbidity index ≥10 (74% versus 58%, P = 0.004), and metastatic disease (89% versus 73%, P = 0.001).
patterns of chemotherapy
Two hundred and twenty-three patients (62%) received palliative chemotherapy for advanced disease ( Table 2 ). The majority of patients (n = 141, 63%) received an anthracyclinebased regimen (Tables 2 and 3) . Patients who received 
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combination therapy were more likely to be <80 years old (81% versus 60%, P = 0.02) than patients who received single-agent chemotherapy. Eighty-two patients (37%) received a reduced dosage regimen since the first cycle of treatment with no significant differences according to the type of chemotherapy (anthracycline-based or other). One hundred and four patients (47%) received two or more lines of chemotherapy.
chemotherapy safety and efficacy
One hundred and ninety-seven patients were assessable for response. Using RECIST, we found that 1 patient (0.5%) had complete response, 35 patients (18%) had partial response, and 78 patients (39.5%) had stable disease. Progressive disease was observed in 83 (42%) patients.
Median PFS of patients treated with first-line chemotherapy was 4 months (95% CI: 2.9-5.1). In univariate analysis, PS ≥ 2 [2.2 months (95% CI: 1.1-3.3) versus 4.5 months (95% CI: 3.3-5.6), P < 0.0001] and a single-agent regimen [3.9 months (95% CI: 3-4.8) versus 8 months (95% CI: 2-14), P < 0.04] were associated with worse PFS. Toxicity was mainly hematological. Seventy-two patients (32%) had at least one grade 3 or 4 adverse event. Thirty-six patients (16%) stopped the treatment early because of adverse events. Patients stopping the treatment because of toxicity were more likely to have experienced a grade 3 or 4 adverse event (69% versus 15%, P < 0.0001).
overall survival
The median follow-up was 40 months (range 36-44). At the time of the analysis, 298 patients had died (83%). Two hundred and eighty-seven deaths (96%) were related to disease progression. OS for the entire cohort was 9 months (95% CI: 7.5-10.5). The 6-month, 1-year, and 2-year OS rates were 62% (95% CI: 57-67), 41% (95% CI: 36-46), and 22% (95% CI: 18-26), respectively. The median OS was 10.9 months (95% CI: 8.3-13.5) for patients who received a specific anticancer treatment and 5.3 months (95% CI: 3.6-7.1) for patients who received BSC only (P = 0.001). On multivariate analysis, age ≥ 80 years, PS ≥ 2, and the number of metastatic sites were significantly associated with worse OS (Table 4, Figure 1 ). After adjustment for these prognostic factors, specific anticancer treatment was not associated with improved outcome (hazard ratio = 1.1, 95% CI: 0.8-1.5, P = 0.47).
discussion
Aging is associated with progressive functional declines and increased prevalence of comorbidities which may influence the management and outcome of cancer patients. To our knowledge, this study is the first describing patterns of treatment and outcomes of elderly patients with advanced STS.
Currently, the standard treatment of patients with metastatic STS is based on a single-agent doxorubicin 75 mg/m 2 21-day cycle [1, 15] . Combination therapies including doxorubicin Our results show that the management of patients >75 years old significantly differs from these guidelines. Indeed, a high proportion (34%) of patients was managed with BSC only. This proportion is comparable with that observed in other tumor types, in particular non-small-cell lung cancer (NSCLC). Indeed, a recent US database Surveillance, Epidemiology and End Results (SEER) study [16] demonstrated that only 26% of 21 285 patients aged >65 years with NSCLCC diagnosed between 1997 and 2002 received chemotherapy. Another recent study of the Manitoba registry [17] reported that only 82 (16.5%) of 497 patients aged ≥70 years with advanced NSCLC received chemotherapy. As observed for other solid tumors such as NSCLC, we demonstrated that sarcoma patients managed with BSC-only were more likely to be ≥80 years old, to have a poor general condition (PS ≥ 2), and to have several comorbidities (age-adjusted Charlson comorbidity index ≥ 10). However, we also found that a significant proportion of patients did not have these poor prognostic features but still did not receive systemic therapy. This last result may reflect a widespread opinion that chemotherapy is not appropriate for elderly patients.
Previous studies identified age, use of standard dose regimen, and Charlson comorbidity index as predictive factors for toxicity in elderly patients with cancer and treated with chemotherapy [18, 19] . A significant proportion of the patients included in our study and managed with chemotherapy did not receive first-line chemotherapy containing anthracycline and/or from the first cycle received a reduced dose compared with the conventional protocol. In fact, data from the literature suggest that age was correlated with a higher risk of cardiac and hematological toxicity related to anthracylines [20] [21] [22] .
Such data may explain the reluctance of oncologists to use this pharmacological class in our series. Interestingly, the International Society of Geriatric Oncology (SIOG) has recently recommended not to alter anthracycline regimens in order to limit toxicity in non-Hodgkin lymphoma (NHL) patients, but to closely monitor cardiac function and cumulative dose limits together [23] . However, we should acknowledge that, unlike for advanced STS, the intent of treatment for NHL is often curative and may justify a more aggressive approach. In addition, the dose of doxorubicin in the standard protocol for NHL (CHOP-21) is 50 mg/m 2 per 21-day cycle and therefore 33% lower than the standard recommended dose in advanced STS.
Overall, our results raise the question of the development of adapted chemotherapy regimens for elderly patients with advanced STS. Liposomal doxorubicin may reduce toxicity, and improve pharmacokinetics compared with free doxorubicin. Indeed, the ability of liposomes to extravasate through leaky tumor vessels contributes to selective localization of liposomal doxorubicin in tumor tissue and to the reduction of toxicity to normal tissue with a lower rate of alopecia, hematological, cardiac, and gastrointestinal toxic effects. There is currently only one published trial that compared liposomal doxorubicin and conventional doxorubicin in advanced STS [24] . This randomized phase II study showed a better safety profile for the liposomal doxorubicin arm and comparable objective response rates. However, the median age of patients included in this study was 53 years. It is therefore difficult to extrapolate these results to elderly patients. The Spanish Sarcoma Group reported recently a single-arm phase II study evaluating a new formulation (non-pegylated) of liposomal doxorubicin in patients with advanced STS. Thirty-seven patients were included with a median age of 74 years. Despite preclinical data suggesting a better tolerability profile, this report showed a high toxicity rate, in particular, with one death due to cardiac toxicity [25] . 
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Alternative regimens to anthracyclines are being evaluated in phase III trials, such as the gemcitabine and docetaxel combination, or trabectidin (http://cancerhelp.cancerresearchuk.org/trials/a-trialcomparing-gemcitabine-docetaxel-with-doxorubicin-softtissue-sarcomas-geddis, http://clinicaltrials.gov/ct2/show/ NCT01189253?term=trabectedin&rank=27). Although these trials did not have an upper age limit in their inclusion criteria, it is unfortunate that they did not integrate an oncogeriatric approach including, for instance, at least stratification by age group.
In addition to the conventional cytotoxic therapies, targeted drugs are in development in advanced STS. Pazopanib, an oral multi-target tyrosine kinase inhibitor (including VEGFR 1-3, PDGFRα and β), has been recently approved by the Food and Drug Administration (FDA) as a second line treatment for advanced STS on the basis of a phase III trial demonstrating a benefit in PFS in comparison with a placebo [26] . The main side-effects were fatigue, diarrhea, nausea, weight loss, and arterial hypertension [26] . Of note, the median age in the pazopanib group was only 56 years. There are only limited data on the pharmacokinetics of tyrosine kinase inhibitors in elderly patients, mostly related to imatinib. Those data show a tendency to increased imatinib plasma concentrations with increasing age in patients with chronic myeloid leukemia or gastrointestinal stromal tumors [27] [28] [29] . This finding might be related to decreased metabolism, and to a lower body mass index among older patients, leading to an increased volume original articles Annals of Oncology distribution. The role of drug interactions cannot be excluded as well, due to a high prevalence of polypharmacy in elderly patients. A new trial project investigating pazopanib as a firstline treatment in advanced STS patients is currently under discussion. We believe that such a trial should plan a specific clinical and pharmacological analysis for elderly patients.
Advanced age, number of metastatic sites, and PS ≥ 2 were the sole independent prognostic factors for OS identified in our series. This result is in agreement with previous studies showing that increasing age and higher PS were independent prognostic factors in studies including advanced STS patients irrespective of their age [30, 31] . Strikingly, we found that patients with PS ≥ 2 had a median OS of only 3.9 months compared with 13.5 months for those with good (<2) PS. Recently, PS ≥ 2 has also been identified as the most significant risk factor for early death (<3 months) in patients with advanced STS treated with first-line chemotherapy [32] . Considering the high risk of early death of patients with poor PS in our series, the decision to administer chemotherapy instead of BSC should be carefully assessed in this setting, given its potential lack of benefit.
In our study, the OS of patients treated with a specific therapy was significantly better than patients receiving BSC only, and close to that observed in younger patients [30, 31] . However, specific treatment was not associated with better outcomes in the multivariate analysis. This does not necessarily mean that chemotherapy is not associated with improved outcomes in patients >75 years of age with advanced STS. Indeed, in our series, we cannot exclude an imbalance in some unidentified prognostic factors that confounds the effects of treatment. In fact, the main limitation of our study, related to its retrospective nature, is that the patients did not undergo a comprehensive geriatric assessment (CGA). The CGA is a multidimensional and multidisciplinary diagnostic procedure [33, 34] used to identify functional, medical, and psycho-social impairments of elderly patients with cancer [35] [36] [37] . This type of assessment is more efficient than the classical assessment of PS or comorbidities to predict survival of elderly patients with cancer [38] . Our results suggest that such an approach would be useful to improve the management of elderly patients with STS. However, in daily clinical practice, the CGA is very difficult to implement for all patients, because it is time consuming and requires a specific geriatric unit. Interestingly, recent studies [39, 40] have proposed to select patients who could benefit from CGA by screening tools such as the G-8 including eight selected items and which could be carried out by a clinical research nurse.
Our study emphasizes the importance of new studies to define better the patterns, benefits, and risks of medical treatment of elderly patients with advanced STS. Such studies should evaluate an approach similar to that proposed by the SIOG for the management of chemotherapy in hormonerefractory prostate carcinomas [41] : standard optimal anthracycline-based regimen for patients considered fit after a careful geriatric evaluation, adapted regimen that remains to be identified for frail patients in order to reduce toxicity, and BSC only for patients considered as definitively unfit for any disease-specific treatment. The design of these future studies should therefore include variables that describe the heterogeneity of the elderly population using appropriate tools such as geriatric screening through assessments such as the G-8, supplemented as necessary by the CGA. These innovative clinical trials should also provide evidence beyond simply improvement of PFS or OS, but also including quality of life, control of symptoms, and time of hospital care.
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